Looking Back, Looking Forward: Current Medications and Innovative Potential Medications to Treat Alcohol Use Disorder

被引：8
作者：
Mason, Barbara J. [1 ,2 ]
机构：
[1] Scripps Res Inst, Pearson Ctr Alcoholism & Addict Res, Dept Mol Med, La Jolla, CA USA
[2] Scripps Res Inst, Dept Mol Med, 10550 N Torrey Pines Rd,TPC-5, La Jolla, CA 92037 USA
来源：
ALCOHOL RESEARCH-CURRENT REVIEWS | 2022年 / 42卷 / 01期
关键词：
alcohol; alcohol use disorder; treatment; medication; disulfiram; naltrexone; acamprosate; DOUBLE-BLIND; DEPENDENCE; ACAMPROSATE; NALMEFENE; EFFICACY; GABAPENTIN; NALTREXONE; TOLERABILITY; DRINKING; STATES;
D O I：
10.35946/arcr.v42.1.11
中图分类号：
R194 [卫生标准、卫生检查、医药管理];
学科分类号：
摘要：
This article is part of a Festschrift commemorating the 50th anniversary of the National Institute on Alcohol Abuse and Alcoholism (NIAAA). Established in 1970, first as part of the National Institute of Mental Health and later as an independent institute of the National Institutes of Health, NIAAA today is the world's largest funding agency for alcohol research. In addition to its own intramural research program, NIAAA supports the entire spectrum of innovative basic, translational, and clinical research to advance the diagnosis, prevention, and treatment of alcohol use disorder and alcohol-related problems. To celebrate the anniversary, NIAAA hosted a 2-day symposium, "Alcohol Across the Lifespan: 50 Years of Evidence-Based Diagnosis, Prevention, and Treatment Research," devoted to key topics within the field of alcohol research. This article is based on Dr. Mason's presentation at the event. NIAAA Director George F. Koob, Ph.D., serves as editor of the Festschrift.
引用
收藏
页数：10
相关论文
共 48 条
[11]  
Gonzales K, 2014, MMWR-MORBID MORTAL W, V63, P213
[12]   A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence [J].
Gual, Antoni ;
He, Yuan ;
Torup, Lars ;
van den Brink, Wim ;
Mann, Karl .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 (11) :1432-1442
[13]   Use of Medications for Alcohol Use Disorder in the US Results From the 2019 National Survey on Drug Use and Health [J].
Han, Beth ;
Jones, Christopher M. ;
Einstein, Emily B. ;
Powell, Patricia A. ;
Compton, Wilson M. .
JAMA PSYCHIATRY, 2021, 78 (08) :922-924
[14]  
Hedegaard Holly, 2017, NCHS Data Brief, P1, DOI 10.15620/cdc:101761
[15]   Drinking Beyond the Binge Threshold: Predictors, Consequences, and Changes in the U.S [J].
Hingson, Ralph W. ;
Zha, Wenxing ;
White, Aaron M. .
AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2017, 52 (06) :717-727
[16]   Pharmacotherapy for Adults With Alcohol Use Disorders in Outpatient Settings A Systematic Review and Meta-analysis [J].
Jonas, Daniel E. ;
Amick, Halle R. ;
Feltner, Cynthia ;
Bobashev, Georgiy ;
Thomas, Kathleen ;
Wines, Roberta ;
Kim, Mimi M. ;
Shanahan, Ellen ;
Gass, C. Elizabeth ;
Rowe, Cassandra J. ;
Garbutt, James C. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (18) :1889-1900
[17]   The Pharmacogenetics of Alcohol Use Disorder [J].
Jones, Jermaine D. ;
Comer, Sandra D. ;
Kranzler, Henry R. .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2015, 39 (03) :391-402
[18]   The Efficacy of Disulfiram for the Treatment of Alcohol Use Disorder [J].
Jorgensen, Charlotte H. ;
Pedersen, Bolette ;
Tonnesen, Hanne .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2011, 35 (10) :1749-1758
[19]   A role for brain stress systems in addiction [J].
Koob, George F. .
NEURON, 2008, 59 (01) :11-34
[20]   Development of pharmacotherapies for drug addiction: a Rosetta Stone approach [J].
Koob, George F. ;
Lloyd, G. Kenneth ;
Mason, Barbara J. .
NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (06) :500-515
12345